The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.
Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01
Open accessAbstract
The structure of VRC01 in complex with the HIV-1 gp120 core reveals that this broadly neutralizing CD4 binding site (CD4bs) antibody partially mimics the interaction of the primary virus receptor, CD4, with gp120. Here, we extended the investigation of the VRC01-gp120 core interaction to the biologically relevant viral spike to better understand the mechanism of VRC01-mediated neutralization and to define viral elements associated with neutralization resistance. In contrast to the interaction of CD4 or the CD4bs monoclonal antibody (MAb) b12 with the HIV-1 envelope glycoprotein (Env), occlusion of the VRC01 epitope by quaternary constraints was not a major factor limiting neutralization. Mutagenesis studies indicated that VRC01 contacts within the gp120 loop D, the CD4 binding loop, and the V5 region were necessary for optimal VRC01 neutralization, as suggested by the crystal structure. In contrast to interactions with the soluble gp120 monomer, VRC01 interaction with the native viral spike did not occur in a CD4-like manner; VRC01 did not induce gp120 shedding from the Env spike or enhance gp41 membrane proximal external region (MPER)-directed antibody binding to the Env spike. Finally, VRC01 did not display significant reactivity with human antigens, boding well for potential in vivo applications. The data indicate that VRC01 interacts with gp120 in the context of the functional spike in a manner distinct from that of CD4. It achieves potent neutralization by precisely targeting the CD4bs without requiring alterations of Env spike configuration and by avoiding steric constraints imposed by the quaternary structure of the functional Env spike.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Novel strategies against these viruses involve delivering mRNA vaccines that target conserved regions such as the haemagglutinin stalk on influenza149, or encodeing broadly neutralizing antibodies such as VRC01 that bind to conserved regions of the CD4 binding site on the HIV gp120 protein206.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [206]
Citations
Cites
HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor
Feng, Y. Y., Broder, C. C., Kennedy, P. E., & Berger, E. A. (1996) · Science · doi:10.1126/science.272.5263.872 · Cited by 4,169
Self-citationIdentification of a major co-receptor for primary isolates of HIV-1
Deng, H., Liu, R., Ellmeier, W., Choe, S. S., Unutmaz, D., Burkhart, M. D., Marzio, P. D., Marmon, S., Sutton, R. E., Hill, C. M., et al. (1996) · Nature · doi:10.1038/381661a0 · Cited by 3,640
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus
Dalgleish, A. G., Beverley, P. C. L., Clapham, P. R., Crawford, D., Greaves, M. F., & Weiss, R. A. (1984) · Nature · doi:10.1038/312763a0 · Cited by 3,539
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
Dragic, T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Nagashima, K. A., Cayanan, C. S., Maddon, P. J., Koup, R. A., Moore, J. P., et al. (1996) · Nature · doi:10.1038/381667a0 · Cited by 3,173
CC CKR5: A RANTES, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1
Alkhatib, G., Combadière, C., Broder, C. C., Feng, Y., Kennedy, P. E., Murphy, P. M., & Berger, E. A. (1996) · Science · doi:10.1126/science.272.5270.1955 · Cited by 2,703
Self-citationT-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV
Klatzmann, D., Champagne, É., Chamaret, S., Gruest, J., Guétard, D., Hercend, T., Gluckman, J. C., & Montagnier, L. (1984) · Nature · doi:10.1038/312767a0 · Cited by 2,435
Antibody neutralization and escape by HIV-1
Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F., Salazar, M. G., Kilby, J. M., Saag, M. S., et al. (2003) · Nature · doi:10.1038/nature01470 · Cited by 2,421
Self-citationThe β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates
Choe, H., Farzan, M., Sun, Y., Sullivan, N. J., Rollins, B. J., Ponath, P. D., Wu, L., Mackay, C. R., LaRosa, G. J., Newman, W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81313-6 · Cited by 2,286
Core Structure of gp41 from the HIV Envelope Glycoprotein
Chan, D. C., Fass, D., Berger, J. M., & Kim, P. S. (1997) · Cell · doi:10.1016/s0092-8674(00)80205-6 · Cited by 2,000
Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
Walker, L., Phogat, S., Chan-hui, P., Wagner, D., Pham, P., Goss, J. L., Wrin, T., Simek, M., Fling, S., Mitcham, J., et al. (2009) · Science · doi:10.1126/science.1178746 · Cited by 1,849
Self-citation
Cited by
Sorted by citations
Items 201–235 of 235
Recurrent mutations drive rapid HIV escape from two broadly neutralizing antibodies in vivo
Romero, E. V., Clyde, A. E., Giorgi, E. E., Westfall, D. H., Azam, W., Taylor, M. L., Caskey, M. F., Feder, A. F., & Cohn, L. B. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2524021123 · Cited by 2
Gálvez, N. M. S., Nitido, A. D., Yoo, S. B., Cao, Y., Deal, C. E., Boutros, C. L., MacDonald, S. W., Albrecht, Y. E. S., Lam, E. C., Sheehan, M. L., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.01.031 · Cited by 4
Self-citationExploring converse molecular mechanisms of anti-HIV-1 antibodies using a synthetic CXCR4 mimic
Haußner, C., Möbius, K., & Eichler, J. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.08.035 · Cited by 2
V3-Independent Competitive Resistance of a Dual-X4 HIV-1 to the CXCR4 Inhibitor AMD3100
Maeda, Y., Terasawa, H., Nakano, Y., Monde, K., Yusa, K., Oka, S., Takiguchi, M., & Harada, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089515 · Cited by 2
Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV
Wahid, B., Ali, A., Idrees, M., & Rafique, S. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2016.08.001 · Cited by 2
Xu, Z., Ho, M., Bordoloi, D., Kudchodkar, S. B., Khoshnejad, M., Giron, L. B., Zaidi, F. I., Jeong, M., Roberts, C. C., Park, Y. K., et al. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1884-4_11 · Cited by 2
Raman, S. C., Mejías‐Pérez, E., Gómez, C. E., García‐Arriaza, J., Perdiguero, B., Vijayan, A., Pérez‐Ruiz, M., Cuervo, A., Santiago, C. A., Sorzano, C. Ó. S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02793 · Cited by 2
Antibody and Cell-Based Therapies against Virus-Induced Cancers in the Context of HIV/AIDS
Joseph, J., Sandel, G., Kulkarni, R., Alatrash, R., Herrera, B. B., & Jain, P. (2023) · Pathogens · doi:10.3390/pathogens13010014 · Cited by 1
Viral glycoprotein-mediated entry and antibody-mediated immunity in HIV-1 and SARS-CoV-2 infection
Grunst, M. W., Li, W., & Mothes, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1733684 · Cited by 1
Paesen, G. C., Chapman, N. S., Westover, J. B., McMillen, C. M., Kuzmina, N. A., Dews, E. A., Myers, L., Stass, R., Montgomery, J. M., Bukreyev, A. A., et al. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1013926 · Cited by 1
Sterjovski, J., Churchill, M. J., Ellett, A. M., Wesselingh, S. L., Ramsland, P. A., & Gorry, P. R. (2012) · Virology · doi:10.1016/j.virol.2012.06.024 · Cited by 1
Khati, M., & Millroy, L. (2012) · InTech eBooks · doi:10.5772/34138 · Cited by 1
Vorobeychik, Y. (2016) · International Joint Conference on Artificial Intelligence · Cited by 1
Predicting Antibody Neutralization Efficacy in Hypermutated Epitopes Using Monte Carlo Simulations
Amengual-Rigo, P., Carrillo, J., Blanco, J., & Guallar, V. (2020) · Polymers · doi:10.3390/polym12102392 · Cited by 1
Wang, Q., Zhang, S., Nguyen, H. T., & Sodroski, J. (2024) · Journal of Virology · doi:10.1128/jvi.01594-23 · Cited by 1
Nguyen, H. T., Qualizza, A., Anang, S., Zhao, M., Zou, S., Zhou, R., Wang, Q., Zhang, S., Deshpande, A. A., Ding, H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.27.462085 · Cited by 1
Ringe, R. P., Das, L., Choudhary, I., Sharma, D. K., Paranjape, R., Chauhan, V. S., & Bhattacharya, J. (2013) · PLoS ONE · doi:10.1371/annotation/6168e62e-6d5b-47a4-bf92-bae95d09d92b · Cited by 1
Manhas, S., Brooker, J. P., Shetler, C., Penrose, K. J., Jaiswal, D. S., Chu, X., Li, W., Kearney, M. F., Mellors, J. W., & Halvas, E. K. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.22.655427 · Cited by 1
Characterization of Envelope-Specific Antibody Response Elicited by HIV-1 Vaccines: A Dissertation
Chen, Y. (2015) · eScholarship@UMassChan · doi:10.13028/m2z88m
Archary, D. (2011) · ResearchSpace (University of KwaZulu-Natal)
Synthesis of Functional and Variable HIV-1 Envelope Glycoproteins
Clapham, P. R. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7729-7_4
Dissection of HIV-1 Env-specific B cell responses in non-human primates
Sundling, C. (2010) · Figshare
Dahodwala, H. (2016) · doi:10.24947/baojh/2/1/107
Phenotypic and Genotypic Features of Macrophage Tropism in HIV-1
Arrildt, K. T. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/9r1d-8780
Beigh, S. (2024) · Natural Resources for Human Health · doi:10.53365/nrfhh/186350
Parallel evolution of the elite neutralizer phenotype in divergent HIV-1 clades
Mesa, K. A., Li, S. W., Hutchinson, J. M., O’Rourke, S. M., Alexander, D. L., Yu, B., Shen, X., Wrin, T., Petropoulos, C. J., Berman, P. W., et al. (2025) · Journal of Virology · doi:10.1128/jvi.00433-25
Fortier, Y. (2019) · theses.fr (ABES) · doi:10.70675/51a7553dzb5caz4997zb48az68f16ad0ee5f
Chhan, C. B., Wan, Y.-H., Wilcox-King, A., Homad, L. J., Aldridge, N. T., Iureniev, R., Stamatatos, L., & McGuire, A. T. (2026) · mSphere · doi:10.1128/msphere.00317-26
Developing Antiviral Vaccines Based on Attenuated Salmonella
Ou, E., & Liu, F. (2026) · Pathogens · doi:10.3390/pathogens15090955
Decoding Clade-Specific bNAb–HIV-1 Env Interactions Using Machine LearningPreprint
Kumar, Y., Lin, S., Dixit, N. M., & Maiti, P. K. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.14.759022
Metadata
- Authors
- Li, Y., O'Dell, S., Walker, L. M., Wu, X., Guenaga, J., Feng, Y., Schmidt, S. D., McKee, K., Louder, M. K., Ledgerwood, J. E., Graham, B. S., Haynes, B. F., Burton, D. R., Wyatt, R. T., & Mascola, J. R.
- Affiliations
- National Institutes of Health (US)
- Scripps Research Institute (US)
- Duke Medical Center (US)
- ORCID
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2011-09
- Volume
- 85
- Issue
- 17
- Pages
- 8954-8967
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC3165784
- OpenAlex
- W2165692875
- Cited by
- 235
- References
- 77
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 5 · 2023: 5 · 2022: 10 · 2021: 14 · 2020: 8 · 2019: 17 · 2018: 18 · 2017: 19 · 2016: 23 · 2015: 22 · 2014: 16 · 2013: 21 · 2012: 30
- FWCI
- 9.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Virology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R01AI033292)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- VRC01, broadly neutralizing antibodies, HIV-1, CD4 binding site, gp120, CD4 receptor, neutralization resistance, steric constraints
- MeSH terms
- Antibodies, Monoclonal, Binding Sites, Enzyme-Linked Immunosorbent Assay, Humans, Models, Molecular, Neutralization Tests, Protein Binding, HIV-1, HIV Envelope Protein gp120, Mutagenesis, Site-Directed, Mutant Proteins, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
